Immunome Inc.
IMNMHeld by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (AL102): Dec 2025. Short interest: 17.9% of float.
Held by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase3 readout (AL102): Dec 2025. Short interest: 17.9% of float.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.